RS5614, a treatment for skin vascular angiosarcoma, has been designated as a rare disease drug by the Minister of Health, Labour and Welfare. Based on promising Phase II results in combination therapy and safety, discussions with PMDA for Phase III commencement continue. The designation offers pricing marketability enhancements and potential post-approval reexamination period extensions. No changes to the full-year forecast for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Renascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4889-20260925-01.pdf","jir_short_summary":"RS5614, a treatment for skin vascular angiosarcoma, has been designated as a rare disease drug by the Minister of Health, Labour and Welfare. Based on promising Phase II results in combination therapy and safety, discussions with PMDA for Phase III commencement continue. The designation offers pricing marketability enhancements and potential post-approval reexamination period extensions. No changes to the full-year forecast for the fiscal year ending March 2027.","jir_summary":"### IR News Highlights\nToday, Renascience Inc. announces that RS5614, our skin vascular angiosarcoma treatment, has been designated as a rare disease drug by the Minister of Health, Labour and Welfare. Phase II results show an objective response rate of 13.3%, disease control rate of 86.7%, median progression-free survival of 4.0 months, and median overall survival of 20.8 months, indicating strong potential. Safety is favorable, and the final trial report has been confirmed as the Clinical Trial Summary Report. Discussions with PMDA for Phase III progression are ongoing. The pricing marketability premium and other incentives are expected to extend the exclusive period for the business. There is no change to the full-year forecast for the fiscal year ending March 2027.\n\n### Outlook and Impact\nThe designation as a rare disease drug is expected to bring benefits such as pricing marketability and extended reexamination periods, aiding post-approval business development and potential grants. In addition to continuing discussions with PMDA for Phase III, the fiscal year ending March 2027 forecast is not immediately affected, but any developments requiring disclosure will be announced in a timely manner.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Renascience, #RareDiseaseDrug, #RS5614","jir_key_figures":"Efficacy rate: 13.3%\nDisease control rate: 86.7%\nMedian progression-free survival: 4.0 months\nMedian overall survival: 20.8 months","jir_meta_title":"Renascience Inc. Designation as a Rare Disease Drug Announcement | September 25, 2026","jir_meta_description":"Renascience's skin vascular angiosarcoma treatment RS5614 has been designated as a rare disease drug. Summary of promising Phase II results, prospects for Phase III, pricing incentives, and PMDA discussions. FY2027 forecast unchanged.","jir_og_title":"Renascience Designation as a Rare Disease Drug | September 25, 2026","jir_og_description":"RS5614 designated as a rare disease drug. Summary of promising Phase II results and future discussions toward Phase III, with anticipated incentives. No change to FY2027 forecast.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-123182","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n